LONDON, ONTARIO--(Marketwire - June 16, 2008) - Critical Outcome Technologies Inc. (TSX VENTURE: COT), announced today that armed with a novel mechanism of action (MOA) for its lead oncology drug candidate COTI-2, the Company will meet with several prospective partners at BIO 2008 taking place June 17-20 in San Diego, CA.
